Dare Bioscience, Inc. quarterly report, Q2 FY2019

Dare Bioscience, Inc. — Q2 2019 Form 10-Q

Reporting period: Three and six months ended June 30, 2019; unaudited. Filed August 14, 2019.

Business context

Daré is a clinical-stage biopharmaceutical company focused on women’s health. Its portfolio includes six clinical-stage and several preclinical product candidates. It has no approved or commercialized products and has generated no product revenue. Research and development is its primary activity.

Financial performance and position

MetricQ2 2019 / June 30, 2019Comparison
RevenueNoneNone in Q2 2018
Operating expenses$3.98 million$3.62 million in Q2 2018
Research and development$2.51 million$2.22 million in Q2 2018
Net loss$3.95 million for Q2; $7.00 million for six monthsQ2 2018: $3.58 million; first half 2018: $11.25 million
Net loss to common shareholders$4.74 million for Q2; $7.79 million for six monthsIncludes a $789,594 deemed dividend from a warrant anti-dilution provision
Loss per common share$0.29 for Q2; $0.57 for six monthsQ2 2018: $0.32; first half 2018: $1.13
Cash and cash equivalents$5.63 million$6.81 million at December 31, 2018
Cash used in operations$6.33 million for six months$4.81 million in first half 2018
Working capitalApproximately $4.6 millionNot provided for the comparable period
Total liabilities$2.18 million$1.10 million at December 31, 2018
Stockholders’ equity$5.08 million$6.73 million at December 31, 2018

Margins are not meaningful because the company reported no revenue. The filing does not report interest-bearing debt; it reports operating lease liabilities of approximately $193,000 at June 30, 2019.

Material changes versus comparable periods

  • Q2 operating expenses increased $358,000 year over year, principally reflecting higher R&D and staffing costs; license expense declined.
  • First-half R&D expense increased $902,000 year over year. The first-half 2018 net loss was larger partly because it included a $5.19 million goodwill impairment.
  • Operating cash use increased by approximately $1.52 million year over year for the first half.
  • In April, the company issued 5.26 million shares and received approximately $5.2 million net proceeds. Shares outstanding rose to 16.68 million from 11.42 million at year-end 2018.
  • The offering triggered a reduction in the February 2018 warrants’ exercise price from $3.00 to $0.98 per share and a $789,594 deemed dividend to common shareholders.

Outlook, commentary, and risks

  • Management estimated existing cash would fund planned operations into Q1 2020, but also stated that resources were insufficient for at least the next 12 months from issuance of the financial statements. The filing identifies substantial doubt about the company’s ability to continue as a going concern and says additional capital is necessary.
  • The company was evaluating equity or debt financings, grants, collaborations, and strategic alliances. It warned that financing may be unavailable or dilutive, and partnerships could require surrendering product or technology rights.
  • Planned milestones included Ovaprene postcoital-study topline data in Q4 2019; a DARE-BV1 Phase 3 study expected to begin in Q4 2019, with potential NDA filing in 2020 if successful; and a DARE-HRT1 Phase 1 study planned for 2019. The company estimated DARE-BV1 Phase 3 and subsequent NDA costs at less than $10 million.
  • In August 2019, after quarter-end, the FDA granted DARE-BV1 Qualified Infectious Disease Product designation. The company said this may provide eligibility for certain review and exclusivity incentives, subject to applicable requirements and approval.
  • Nasdaq had notified the company that its share price was below the $1.00 minimum bid requirement, with a December 18, 2019 compliance deadline. The filing noted that continued eligibility for an additional compliance period could require stockholders’ equity of at least $5 million and potentially additional equity financing.
  • Key risks include clinical or regulatory delays or failure, dependence on third-party developers and manufacturers, uncertain reimbursement and market acceptance, license obligations, intellectual-property risks, and the need for additional capital.

Important facts for investors to verify

  • Whether the company raised sufficient capital after the filing to fund operations beyond its stated Q1 2020 runway and address the going-concern uncertainty.
  • Progress and results of the Ovaprene study and the timing and outcome of the planned DARE-BV1 Phase 3 program.
  • Whether the company regained Nasdaq minimum-bid compliance and maintained the equity needed for any additional compliance period.
  • The actual cash, dilution, and warrant consequences of future financing, including outstanding warrants and deferred license payments that may be settled in shares.
  • Whether grant reimbursements and remaining NIH award funding were received; some award funding was contingent on study results and fund availability.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.